Home › Funds › SR ONE CAPITAL MANAGEMENT, LP › ENGN
SR ONE CAPITAL MANAGEMENT, LP position in ENGN
ENGENE THERAPEUTICS INC · Health Care
SR ONE CAPITAL MANAGEMENT, LP reported holding 747,750 shares of ENGN (ENGENE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 0.13% of its reported portfolio and ranking #17 among its reported holdings. SR ONE CAPITAL MANAGEMENT, LP has disclosed ENGN holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How SR ONE CAPITAL MANAGEMENT, LP's ENGN position evolved
SR ONE CAPITAL MANAGEMENT, LP first disclosed a stake in ENGN in Q2 2024 at 500,000 shares (US$4.7M). The position peaked in Q4 2025 at 747,750 shares, worth US$6.8M. Across 10 filings, SR ONE CAPITAL MANAGEMENT, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 747,750 shares valued at US$1.5M. Notable position changes include a 50% increase in Q3 2024.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 500.00K | $4.71M | New |
| Q3 2024 | 747.75K | $4.94M | Add |
| Q4 2024 | 747.75K | $4.97M | Hold |
| Q1 2025 | 747.75K | $3.35M | Hold |
| Q2 2025 | 747.75K | $2.72M | Hold |
| Q3 2025 | 747.75K | $5.11M | Hold |
| Q4 2025 | 747.75K | $6.75M | Hold |
| Q1 2026 | 747.75K | $5.09M | Hold |
| Q2 2026 | 747.75K | $1.29M | Hold |
| Q3 2026 | 747.75K | $1.50M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ENGN and 13F data
ENGN (ENGENE THERAPEUTICS INC) is a Health Care company. 23 other funds we track also report a position in ENGN — the largest reported positions include FCPM III SERVICES B.V. (US$19.3M), BML Capital Management, LLC (US$13.3M), ACORN CAPITAL ADVISORS, LLC (US$7.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ENGN
- FCPM III SERVICES B.V. 9.63M sh · $19.27M · Q3 2026
- BML Capital Management, LLC 6.67M sh · $13.34M · Q3 2026
- ACORN CAPITAL ADVISORS, LLC 3.81M sh · $7.62M · Q3 2026
- Nextech Invest Ltd. 2.32M sh · $4.65M · Q3 2026
- Peapod Lane Capital LLC 1.04M sh · $2.08M · Q3 2026
- Omega Fund Management, LLC 876.36K sh · $1.75M · Q3 2026
- Aldebaran Capital, LLC 657.32K sh · $1.31M · Q3 2026
- Kynam Capital Management, LP 457.86K sh · $915.71K · Q3 2026
- Rangeley Capital, LLC 287.90K sh · $575.80K · Q3 2026
More on SR ONE CAPITAL MANAGEMENT, LP
FAQ
How long has SR ONE CAPITAL MANAGEMENT, LP held ENGN?
SR ONE CAPITAL MANAGEMENT, LP has disclosed ENGN holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is SR ONE CAPITAL MANAGEMENT, LP's current position in ENGN?
As of Q3 2026, SR ONE CAPITAL MANAGEMENT, LP holds 747.75K shares of ENGN (ENGENE THERAPEUTICS INC), valued at $1.50M, representing 0.13% of its reported portfolio and ranking #17.
Has SR ONE CAPITAL MANAGEMENT, LP been buying or selling ENGN?
In the latest 13F filing (Q3 2026), SR ONE CAPITAL MANAGEMENT, LP held unchanged its position in ENGN. The position peaked in Q4 2025 at 747.75K shares.
Which other funds hold ENGN?
Other major institutional holders of ENGN include FCPM III SERVICES B.V., BML Capital Management, LLC, ACORN CAPITAL ADVISORS, LLC, among 23 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.